Welcome to CABS 2019 BioPacific Conference

Date: June 22, 2019 (Saturday), 8am – 7pm

 

Location: San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA

Early bird rate ends on June 7, please register ASAP! 

http://www.cabsweb.org/events/3286497/Welcome+to+CABS+2019+BioPacific+Conference/

Registration using a computer is preferred.

Want to register using iPhone? Please read this or use the link below

(http://cabsweb.org/resources/Documents/2019%20BioPacific/iPhone%20Registration-Final.png)

Please contact info@cabsweb.org if there are any questions.

Highlights of 2019 Biopacific Conference:

  • 8 podium talks, 3 panel discussions, 50+ sponsors, 600+ attendees expected
  • 10 years growth story of BeiGene: how the leading Chinese biotech achieved 7 billion of market cap
  • Cure HIV: Gilead’s next battle after its success in HCV
  • Denali’s new approaches to neurodegenerative disease
  • Discovery story behind Talazoparib: 2018 approved therapeutics for breast cancer
  • Recent advances in cancer biomarker and precision medicine
  • Next wave of cancer therapies and combinations
  • The latest foreign investment regulation and policy

 

Confirmed Speakers and Panelists:

 

  • Ron Mazumder, PhD, Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech
  • Jason Liu, PhD, MBA, CEO, WuXi Diagnostics
  • John Oyler, Founder, CEO and Chairman of BeiGene
  • Romas Geleziunas, PhD, Executive Director, Gilead Sciences
  • Joseph Benkert, Senior Advisor, Morrison Foerster
  • Zach Sweeney, PhD, Head of Therapeutic Discovery, Denali Therapeutics
  • Shivaani Kummar, MD, Professor of Medicine and Director of Phase I Clinical Research Program (Oncology), Stanford University
  • Leonard Post, PhD, CSO, Vivace Therapeutics
  • Jun Xiang, PhD, General Manager, ChemPartner Biologics
  • Michael Su, MS, JD, Attorney, Intellectual Property Law, Finnegan
  • Vivien Wang, MS, Partner, Deloitte
  • Tao He, PhD, Co-Founder and SVP, Joinn Biologics
  • Connie Sun, PhD, SVP, Pharmaron
  • Mike Chen, CEO, AcroBio
  • Scott Liu, PhD, CEO, Henlius
  • Jean Cui, PhD, CSO, Turning Point Therapeutics
  • Mark Nevins, MS, VP of Business Development, Apexigen
  • Peiwen Yu, PhD, VP of Discovery Biology, Exelixis
  • Yanyan Zheng, PhD, Principle Scientist, Merck
  • More to come…

 

Conference agenda (Tentative)

 

Keynote: Biomarkers and Translational Research in Cancer Therapy
Ron Mazumder, PhD, Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech
New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation
Jason Liu, PhD, MBA, CEO, WuXi Diagnostics
CABS K. Fong Award in Life Sciences
Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures
Awardee: John Oyler, Founder, CEO and Chairman of BeiGene
Designing Therapies to Cure HIV
Romas Geleziunas, PhD, Executive Director, Gilead Sciences
Fireside Chat
Moderator: Alex J. Zhang, PhD, MBA, CEO, Hanhai Silicon Valley
Jun Xiang, PhD, General Manager, ChemPartner Biologics
Talk title: TBA
Joseph Benkert, Senior Advisor, Morrison Foerster
Panel Discussion: IP, legal and investment in Life Sciences
Moderator: Huijun Zhou, PhD, iDNA
Panelists:
Michael Su, MS, JD, Attorney, Intellectual Property Law, Finnegan
Vivien Wang, MS, Partner, Deloitte
Sponsor Workshop from Beijing VitalStar Biotechnology
New Approaches to Neurodegenerative Disease Drug Discovery and Development
Zach Sweeney, PhD, Head of Therapeutic Discovery, Denali Therapeutics
Panel Discussion: Innovative and Collaborative Contract Services to Accelerate Drug Development
Moderator: Jiangwen Majeti, PhD, MBA, Genentech
Panelists:
Tao He, PhD, Co-Founder and SVP, Joinn Biologics
Connie Sun, PhD, SVP, Pharmaron
Mike Chen, CEO, AcroBio
Applying Precision Medicine One Patient at a Time
Shivaani Kummar, MD, Professor of Medicine and Director of Phase I Clinical Research Program (Oncology), Stanford University
Panel Discussion: innovative therapy in oncology, what is next?
Moderator: Cheni Kwok, PhD, CLP, Linear Dreams
Panelists:
Scott Liu, PhD, CEO, Henlius
Jean Cui, PhD, CSO, Turning Point Therapeutics
Mark Nevins, MS, VP of Business Development, Apexigen
Peiwen Yu, PhD, VP of Discovery Biology, Exelixis
Yanyan Zheng, PhD, Principle Scientist, Merck
Talazoparib: From Virtual Drug Discovery to FDA Approval
Leonard Post, PhD, CSO, Vivace Therapeutics